Murthy, Vishnu
Appiah-Kubi, Emmanuel
Nguyen, Kathleen
Thin, Pan
Hotta, Masatoshi
Shen, John
Drakaki, Alexandra
Rettig, Matthew
Gafita, Andrei
Calais, Jeremie http://orcid.org/0000-0002-8839-4379
Sonni, Ida
Article History
Received: 18 July 2023
Accepted: 6 September 2023
First Online: 2 October 2023
Declarations
:
: Due to the retrospective design, this study was approved by the institutional review board with a waiver of informed consent (IRB#20-000954).
: Due to the retrospective design, this study was approved by the institutional review board with a waiver of informed consent (IRB#20-000954).
: Jeremie Calais reports prior consulting services for Advanced Accelerator Applications, Astellas, Blue Earth Diagnostics, Curium Pharma, DS Pharma, EXINI, GE Healthcare, Isoray, IBA RadioPharma, Janssen Pharmaceuticals, Lightpoint Medical, Lantheus, Monrol, Novartis, Progenics, POINT Biopharma, Radiomedix, Sanofi, and Telix Pharmaceuticals outside of the submitted work. Matthew Rettig reports consulting services for INmune Bio, Amgen, Ambrx, and Orphagen, research funding from Lantheus, Novartis, Merck, ORIC, Xencor, Astellas, Pfizer, and Oncopia, speakers’ fees from Janssen and Bayer, and a patent for Inhibitors of the N-terminal Domain of the Androgen Receptor. No other potential conflicts of interest relevant to this article exist.